170 related articles for article (PubMed ID: 9291814)
1. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality.
Nordal RR; Thoresen SO
Eur J Cancer; 1997 May; 33(6):907-11. PubMed ID: 9291814
[TBL] [Abstract][Full Text] [Related]
2. Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008.
Boll D; Verhoeven RH; van der Aa MA; Pauwels P; Karim-Kos HE; Coebergh JW; van Doorn HC
Int J Gynecol Cancer; 2012 May; 22(4):599-606. PubMed ID: 22398706
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007.
Gao Y; Meng H; Zhang Y; Jiao T; Hui N
Int J Clin Exp Pathol; 2014; 7(4):1616-24. PubMed ID: 24817958
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Tumour Biol; 2011 Jun; 32(3):451-9. PubMed ID: 21161468
[TBL] [Abstract][Full Text] [Related]
5. Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database.
Hosh M; Antar S; Nazzal A; Warda M; Gibreel A; Refky B
Int J Gynecol Cancer; 2016 Jul; 26(6):1098-104. PubMed ID: 27177280
[TBL] [Abstract][Full Text] [Related]
6. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.
Brooks SE; Zhan M; Cote T; Baquet CR
Gynecol Oncol; 2004 Apr; 93(1):204-8. PubMed ID: 15047237
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of parity in 493 uterine sarcoma patients.
Albrektsen G; Heuch I; Wik E; Salvesen HB
Int J Gynecol Cancer; 2009 Aug; 19(6):1062-7. PubMed ID: 19820369
[TBL] [Abstract][Full Text] [Related]
8. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.
Abeler VM; Røyne O; Thoresen S; Danielsen HE; Nesland JM; Kristensen GB
Histopathology; 2009 Feb; 54(3):355-64. PubMed ID: 19236512
[TBL] [Abstract][Full Text] [Related]
9. [Uterine sarcoma. Apropos of 25 cases].
Bennani O; Himmi A; Laghzaoui M; Aderdour M
Rev Fr Gynecol Obstet; 1995 Jan; 90(1):12-6. PubMed ID: 7899765
[TBL] [Abstract][Full Text] [Related]
10. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
11. Is there an increase in the incidence of uterine carcinosarcoma in north-east Scotland? A 19 years population-based cohort study.
Gurumurthy M; Lahiri R; Scott N; Miller I; Cruickshank ME; Parkin DE
Scott Med J; 2013 May; 58(2):88-94. PubMed ID: 23728753
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years' clinical experience from a tertiary care center in Pakistan.
Khan SR; Soomar SM; Asghari T; Ahmed A; Moosajee MS
BMC Cancer; 2023 Jun; 23(1):510. PubMed ID: 37277708
[TBL] [Abstract][Full Text] [Related]
13. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma.
Akahira J; Tokunaga H; Toyoshima M; Takano T; Nagase S; Yoshinaga K; Tase T; Wada Y; Ito K; Niikura H; Yamada H; Sato A; Sasano H; Yaegashi N
Oncology; 2006; 71(5-6):333-40. PubMed ID: 17690557
[TBL] [Abstract][Full Text] [Related]
14. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II.
Visnovsky J; Kudela E; Slavik P; Krkoska M; Buocik P; Szepe P; Danko J
Neuro Endocrinol Lett; 2015; 36(8):750-7. PubMed ID: 26921575
[TBL] [Abstract][Full Text] [Related]
15. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
16. [A clinical analysis of 153 uterine sarcomas].
Bai P; Sun J; Chao H
Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):163-7. PubMed ID: 9596892
[TBL] [Abstract][Full Text] [Related]
17. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
[TBL] [Abstract][Full Text] [Related]
18. Treatment of early uterine sarcomas: disentangling adjuvant modalities.
Zagouri F; Dimopoulos AM; Fotiou S; Kouloulias V; Papadimitriou CA
World J Surg Oncol; 2009 Apr; 7():38. PubMed ID: 19356236
[TBL] [Abstract][Full Text] [Related]
19. Uterine carcinosarcomas: incidence and trends in management and survival.
Arrastia CD; Fruchter RG; Clark M; Maiman M; Remy JC; Macasaet M; Gates EJ; Di Maio T; Marzec T
Gynecol Oncol; 1997 Apr; 65(1):158-63. PubMed ID: 9103406
[TBL] [Abstract][Full Text] [Related]
20. Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri.
Vongtama V; Karlen JR; Piver SM; Tsukada Y; Moore RH
AJR Am J Roentgenol; 1976 Jan; 126(1):139-47. PubMed ID: 175673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
